Zepbound vs Mounjaro: Same Drug, Two Names, One Big Difference

They are the same molecule. I had to read that three times

Zepbound and Mounjaro are both tirzepatide. Same drug, same manufacturer, same active ingredient going into your body.

I spent an embarrassing amount of time trying to work out the difference between them before I understood that pharmacologically there isn't one worth explaining to a patient. The difference is administrative, and it is also, annoyingly, the thing that decides what you pay.

Why one drug has two names

Drugs get approved for a specific use, proven by a specific trial. Tirzepatide was tested twice, for two different jobs.

The obesity trial was SURMOUNT-1: 2,539 adults, 72 weeks, randomized to 5 mg, 10 mg, 15 mg or placebo. Average weight change was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo¹. That trial is the basis for Zepbound, the weight-management label.

And here is the detail that explains the whole thing: SURMOUNT-1 excluded people with diabetes. Deliberately. It was answering "does this work for obesity in people who do not have diabetes."

The diabetes question was answered by a different trial program, and that is where Mounjaro comes from — the type 2 diabetes label.

Two names, because two questions, because that is how drug approval works. Not because one is stronger, newer or better.

So why does it matter which one is on the box?

Because insurers do not price a molecule. They price an indication.

A plan that covers Mounjaro for type 2 diabetes may flatly refuse Zepbound for weight management, and the pharmacy is not being difficult when it tells you that — it is reading a different line in the formulary. Same chemical, different answer.

This is also why you will see wildly different numbers quoted for what is functionally one drug. Looking across telehealth sellers this month, the same tirzepatide shows up at a few hundred dollars under one name and near two thousand under another, depending on which label and which supply route is involved.

The supply question hiding underneath

There is a second reason the two names matter, and it shows up on the shelf rather than the formulary.

When a brand-name GLP-1 is scarce, the scarcity does not hit both labels evenly — they are manufactured and allocated as separate products even though the molecule is identical. So "is it available" and "is it covered" can have different answers for what is chemically the same injection, in the same month, at the same pharmacy.

That is also the gap compounded sellers stepped into, and why so much of this roster sells a compounded version of a molecule you could in principle get under two brand names. Worth knowing which of those three things you are actually being offered.

What I would actually do with this

If a clinician offers you tirzepatide, the useful question is not "which is better." It is: which label are you writing, and what does my plan do with that word?

Two more worth asking:

• If my plan covers one and not the other, is the one it covers clinically appropriate for me — or would taking it mean claiming a diagnosis I do not have? That second thing is not a loophole to be clever about. It is fraud, and clinicians will not do it.
• If neither is covered, what does this cost cash, at the dose I would actually end up on rather than the starting one?

The bit I want to say plainly

I have watched people in group chats conclude that Mounjaro is "the stronger one" or that Zepbound is "the newer one." Neither is true. They are the same molecule with different paperwork, and the paperwork is about who was in the trial, not about how well it works.

Knowing that will not get your insurance to say yes. But it does stop you switching sellers hoping for a different drug, when what you are actually shopping for is a different word on a form.

None of this is medical advice, and I am a mom who reads trial papers, not your clinician. Tirzepatide is not established as safe in pregnancy or while breastfeeding.